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1.1 Lung Cancer 
1.1.1 Epidemiology 
Lung cancer is the leading cause of cancer related deaths globally, accounting for 1.4 
million deaths worldwide in 2008 (1). Also in Norway is lung cancer is the major cancer 
killer. In 2010, 1559 men and 1267 women were diagnosed with lung cancer, and it was 
registered 1275 and 946 lung cancer deaths the same year (2).  This accounts for more deaths 
than for prostate cancer, breast cancer and practically twice the number of deaths from colon 
cancer. In Norway, six individuals die from lung cancer every day. While the lung cancer 
incidence rates for men peaked in the mid nineties and have declined the last years, the rates 
for women have continued to rise (Figure 1).  
 
 
Figure 1: Trends in incidence and mortality rates and 5-year relative survival proportions 




Worldwide, smoking is believed to account for 80 % of lung cancer cases in men and 
at least 50 % in women (1). In western countries, 15-20 % of lung cancers are considered to 
have other causes than smoking. Other known risk factors are asbestos, arsenic, radon and 
polycyclic aromatic hydrocarbons (1), and from China it is believed that a high fraction of 
lung cancers are caused by indoor pollution from unventilated coal-fueled stoves (3). In 
Norway, the incidence rate closely mirrors the smoking habits. There has been a significant 
decline among male daily smokers since the early seventies, while females maintained their 
smoking habits until the late nineties before a decline was observed (4)(Figure 2). 
 
Figure 2: Female and male daily smokers and occasional smokers in Norway 16-74 year-
olds. (adapted from www.ssb.no; Statistics Norway 2012.) 
 
1.1.2 Histopathology 
Lung cancer is clinically and histopathologically divided into non-small cell lung 
cancer (NSCLC; 85% of lung cancers) and small cell lung cancer (SCLC; 15% of lung 
cancers). The largest subgroups of NSCLC are adeno-, squamous cell and large cell 
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carcinomas. In recent years, adenocarcinomas have become the dominant subgroup, pushing 
squamous cell carcinoma down to 2nd place (5).  
Our database was established in 2005-2006, and the pathology classification was 
according to the updated work by the World Health Organization from 2004 (6). In 2011, 
Travis and coworkers released a new, multidiciplinary classification for lung adenocarcinoma. 
One of the main differences from the 2004 classification is that the term bronchioloalveolar 
carcinoma (BAC) is replaced by adenocarcinoma in situ (AIS), lepidic predominant 
adenocarcinoma (LPA) or invasive mucinous adenocarcinoma (7). As we have included the 
BACs in the adenocarcinoma group when doing the statistics, these changes will have no 
practical influence on the results of our papers.  
To get an exact pathologic diagnosis is essential. There are prognostic differences 
between histologic subgroups. Moreover, recent years drugs with effects only within certain 
subgroups with distinct molecular features have been developed. Whereas traditional special 
stainings and immunohistochemistry were used to differentiate between subgroups of 
NSCLC, more sophisticated methods is today needed to differentiate between subtypes of 
interest.  
While NSCLC treatment was rather homogenous earlier, today’s therapy is becoming 
more individualized. Pemetrexed and bevacizumab are only used in non-squamous cell 
carcinomas (8;9). In western countries about 10% of lung adenocarcinomas have mutation in 
the epidermal growth factor receptor (EGFR). In 1058 Norwegian patients tested, the 
mutation rate was 11.6% (10). These tumors are associated with a better response to treatment 
with tyrosine kinase inhibitors (TKIs) (11). 5-7 % of lung adenocarcinomas have a 
translocation in the anaplastic lymphoma kinase (ALK) gene, which make them more likely 
to respond to treatment with the ALK/MET inhibitor crizotinib (12). Mutation in the KRAS 
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gene may also be important to detect. Around 30 % of adenocarcinomas have this mutation, 
which is associated with resistance to TKI treatment (13;14). 
1.1.3 Diagnosis, staging (TNM) and prognosis 
Most lung cancer patients have symptoms at the time of diagnosis, which often means 
that the disease is discovered at an advanced stage beyond the chance of cure. In 2011, the US 
National Lung Screening Trial (NLST) reported a significant mortality reduction from CT 
screening of high risk patients (15). However, a screening program for lung cancer has still 
not started. Results from supplemental studies, and a more optimal selection of high risk 
groups are warranted before screening programs should be implemented (16).  
Chest X-ray is often the primary imaging examination done when lung cancer is 
suspected, but where there is a strong suspicion a CT of the lungs including the 
supraclavicular fossa and the upper abdomen with adrenal glands should be done. If a lung 
tumor is detected on CT scan, bronchoscopy, endobronchial ultrasound or esophagal 
ultrasound is done for histology or cytology. If unsuccessful, CT guided biopsy is mandatory 
if the tumor is peripheral. Today PET-CT is often performed to decide the final TNM. PET-
CT is important for differentiating benign from malignant masses and for detecting possible 
distant metastases. Brain MRI is often done to rule out possible brain metastases, especially 
for small cell lung cancer.  
The new TNM classification for lung cancer was published in 2009 by IASCL (17) 
(Table 1). This classification is important in order to separate patients according to proper risk 
groups. This is essential in selecting the most appropriate treatment regimen.    
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Table 1: The seventh edition of TNM classifications and stage groupings (adapted from ref 17) 
Stage Sub-
stage 




 Tx Primary tumor not assessed or 
proven only by cells 
N0 No regional lymph node metastasis M0 (no distant metastasis)  
Stage 0  Tis carcinoma in situ N0 M0  
T1a Tumor ≤ 2 cm M0 IA 
T1b Tumor ≤ 3 cm >2 cm 
N0 
 
73% Stage I 
IB T2a Tumor ≤ 5cm > 3 cm N0 M0 58% 
T1a N1 metastasis in ipsilateral hilar LN M0 
T1b N1  
T2a N1  
IIA 
T2b Tumor ≤ 7 cm > 5 cm N0  
46% 
T2b N1 M0 
Stage  II 
IIB 
T3 Tumor > 7 cm/invading chest 
wall, pleura or pericardium/in the 
main bronchus <2 cm from carina 
N0  
36% 
T1 N2 metastasis in ipsilateral mediastinal 
and/or subcarinal lymph nodes 
M0 
T2 N2  
T3 N1  
T3 N2  
T4 Tumor invading mediastinum, 
heart, great vessels, trachea, 
esophagus, vertebral body, carina or 
tumor in another ipsilateral lobe 
N0  
IIIA 
T4 N1  
24% 
T4 N2 M0 
Stage III 
IIIB 
Any T N3 metastasis in contralateral mediastinal, 
hilar, scalene or supraclavicular LN 
 
9% 
Stage IV IV Any T Any N M1A pleural or pericardial 
effusion or separate tumor in 
contralateral lobe 
M1B distant metastasis 
13% 
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1.1.4 Treatment of NSCLC 
Surgery is the treatment of choice for potentially curable NSCLC patients, and was for 
a long time the only therapy for this group. During the last decade, adjuvant chemotherapy 
has become routine in stage II-IIIA patients (18). Today, stage IIIA and IIIB patients are 
treated with radiochemotherapy (19). Our cohort was treated before introduction of adjuvant 
chemotherapy and radiochemotherapy. In more advanced stages of the disease, chemotherapy 
is the main systemic therapy, although targeted drugs have been introduced in specific 
NSCLC subgroups (see 1.1.4.2).  
1.1.4.1 Curable NSCLC 
Surgery is the most important treatment modality, and stage I patients are operated 
with no adjuvant or neoadjuvant treatment. For all stage II and stage IIIA patients (N1 and 
pN2) disease, surgery and adjuvant chemotherapy is the treatment of choice. pN2 patients 
should receive thoracic radiation after adjuvant chemotherapy. Four cycles with cisplatin and 
vinorelbine is the preferred adjuvant regimen (18). Stage IIIA cN2 patients are treated with 
radiation in combination with chemotherapy (19).  
In otherwise resectable tumors in medically inoperable patients, standard treatment is 
radiation (66-70 Gy) with curative intention, with or without chemotherapy. Postoperative 
radiotherapy is indicated at unfree surgical margins, and for patients with pN2 or pN3 disease 
(20).  
1.1.4.2 Advanced NSCLC 
About 70 % of lung cancer patients are diagnosed when the disease has reached a stage 
where cure is not possible (21). Some of these patients may not receive any treatment due to 
severely reduced performance status in addition to well advanced disease, but the majority 
receives chemotherapy, targeted therapies or radiotherapy treatment with palliative aim.  
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Platinum doublets, a platinum based drug in combination with vinorelbine, gemcitabine, 
pemetrexed or docetaxel are the most usual combinations in first line treatment of NSCLC. 
Chemotherapy in NSCLC is administered as 3-4 cycles with a platinum doublet. In Norway 
carboplatin and vinorelbine is the regimen of choice based on the efficacy and toxicity profile 
(22). Similar to other cancers, some studies are suggesting that maintenance therapy may have 
effect (23). Pemetrexed doublet is used only in patients with non-squamous histology, as it 
has inferior effect in squamous cell carcinomas when compared with other doublets (9;24). 
Besides, pemetrexed maintenance, immediately after four platin-based doublet courses, has 
shown significantly better progression free survival (PFS) and overall survival (OS) (25;26).   
In patients with EGFR tyrosin kinase mutation or ALK translocation, tyrosine kinase 
inhibitors (TKIs) or crizotinib is administered, respectively. For the mentioned genetic 
alterations, EGFR TKIs have a superior effect in first line therapy, while crizotinib have 
proven its superiority in second line treatment (27-29).   
1.2 Angiogenesis 
1.2.1 Angiogenesis 
As stated by Folkman in 1971, a tumor can only reach a size of 1-2 mm3 without 
developing new blood vessels (30). Tumor angiogenesis has throughout the years become one 
of the central topics in cancer research, and was in the renowned review by Hanahan and 
Weinberg established as one of the hallmarks of cancer (31). Angiogenesis is the process 
where blood vessels are formed from preexisting ones, in contrast to vasculogenesis, which is 
the forming of new vessels as happens in embryogenesis. Blood vessels are normally stable 
structures, and endothelial cells are among the cells in the body with the slowest turnover. 
However, when a tumor starts evolving, the need for nutrients and oxygen to the new cells 
makes development of new vessels necessary, and the turnover of endothelial cells is speeded 
up. The process where angiogenesis is turned on is called the angiogenic switch (32). 
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Different signalling molecules are believed to contribute to trigging the shift from a quiescent 
state to an active angiogenic state (33;34).  
One of the most important players in stimulating angiogenesis is the vascular 
endothelial growth factor (VEGF), and in particular VEGF-A. During the angiogenic switch, 
the matrix metalloproteinase-9 (MMP-9) is contributing in increasing the bioavailability of 
VEGF-A. MMP-2 and -7 are also important factors in stimulating angiogenesis. But the 
complexity of this process is evident, as the same MMPs also play central roles in the 
production of angiogenesis inhibitors (35).   
 
1.2.2 Biomarkers associated with angiogenesis covered in this 
thesis 
1.2.2.1 Matrix metalloproteinases (MMPs) 
Matrix metalloproteinases are a family of zinc-dependent endopeptidases. They are 
involved in degradation of the extracellular matrix, and also in various other physiological 
processes including regulation of inflammatory processes, signaling for cell growth and 
angiogenesis (36;37).  MMPs can have both pro- and antiangiogenic properties. They are 
involved in the “angiogenic switch” in tumors, where VEGF is made available and 
angiogenesis is stimulated (38;39). But MMPs may also inhibit angiogenesis, as they generate 
various angiogenesis inhibitors. Three of these inhibitors are endostatin, tumstatin and 
angiostatin (40-42).  
1.2.2.2 MicroRNAs (miRNAs)  
MicroRNAs are small non-coding RNAs (19-22 nucleotides). They post-
transcriptionally regulate the stability and translation of mRNAs. Today, we know more than 
1500 human miRNAs. It is assumed that they regulate approximately 30 % of the genes. 
miRNAs play an important role in various processes, such as differentiation, proliferation, 
 15 
apoptosis, angiogenesis, metabolism, development, immunity and stress response (43;44). 
They are located at sites known to be altered in cancer, and are frequently deregulated (45). 
miRNAs have become interesting potential therapeutic targets. Novel miRNA targeting 
agents have not reached clinical trials, but considerable research is going on in this field 
(46;47).   
The mature single-
stranded miRNAs are processed 
from larger double-stranded 
precursor transcripts with a 
characteristic hairpin structure. In 
the nucleus, the first step of 
sequential cropping of the 
transcript (pri-miRNA) is carried 
out by Drosha, a RNase III 
endonuclease. The resulting 70-
90 nucleotide pre-miRNA is 
transported to the cytoplasm by 
the export receptor exportin 5. In 
the cytoplasm another RNase III 
endonuclease, Dicer, performs 
cropping of the pre-miRNA 
resulting in a double-stranded 
miRNA duplex. One of the 
strands is loaded into the RNA-
induced silencing complex 
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(miRISC) while the other strand is degraded. The miRNA is finally base paired with its target 
mRNA (Figure 3) (48). 
MicroRNAs are involved in angiogenesis (49-51). Indications of this were found in a 
stydy where Dicer-knockout mice died within 14.5 days of gestation due to lack of 
angiogenesis. miRNAs have also been found to regulate well known angiogenetic factors, 
such as VEGF, and thereby influencing angiogenesis (49). In a pilot study carried out by our 
research group, we screened the expression of 281 miRNAs in NSCLC tissues. Herein, 
pathway analyses showed that the gene set connected to angiogenesis-related miRNAs had 
the highest impact (52).   
1.3 Tumor and stroma 
Most research on cancer has been concentrated on the tumor cells alone, but recent 
years it has become evident that the tumor cells live in a close and dependent relationship 
with their surroundings, called the tumor stroma. Among other components, the tumor stroma 
consists of fibroblasts, endothelial cells, pericytes, immune cells and extracellular matrix. 
When a cancer cell resides in the stromal compartment, it interacts with the surrounding 
environment. This can make conditions more suitable for tumor growth, as the stroma 
changes from its usual protective role in cancer development (53). In a growing tumor, there 
is a continuous paracrine communication between tumor cells and the surrounding stromal 
cells. Today there is an increasing interest in studying the interaction between tumor cells and 
their surroundings to understand the dynamics of the growing tumor.  
Two of the most interesting cell-types of the tumor stroma are immune cells and cancer 
associated fibroblasts (CAFs). The latter are activated fibroblasts releasing mediators like 
growth factors, cytokines and immune modulators (54). The origin of CAFs is still 
controversial. They may derive from local resident fibroblasts, bone marrow-derived 
mesenchymal cells, pericytes, smooth muscle cells or even from epithelial cells via epithelial-
 17 
mesenchymal transition (EMT). They represent the largest cell population in the tumor stroma 
(55). CAFs may influence tumor growth by producing growth factors like transforming 
growth factor-beta (TGF-β), which promotes tumorigenesis (56). Also, angiogenesis may be 
altered, as CAFs are involved in the PDGF pathway (57). CAFs also contribute to migration 
and metastasis by modulating the stroma in a paracrine manner through secretion of proteases 
like MMPs, cathepsins and plasminogen activators (58). 
The abundance of inflammatory cells is a known feature of the tumor stroma, especially 
in NSCLC. An adaptive response of the immune system may create a favorable 
microenvironment for cancer development (59). Experiments have shown that chronic 
inflammation promotes carcinogenesis (60). 
MicroRNAs play a distinct role in the development of the microenvironment (61). 
Among other miRNAs, miR-21 is found to contribute to the differentiation of fibroblasts to 
CAFs (62;63). Several miRNAs are deregulated in CAFs relative to normal fibroblasts.  
Effects of miRNAs on angiogenesis also show the impact in the stromal compartment of these 
small molecules. Much is still unknown about the paracrine mediators of the miRNA-
mediated response. More knowledge about these mediators will be essential for understanding 




2 AIMS OF THESIS 
The aim of this thesis was to investigate the prognostic impact of angiogenesis related 
markers in NSCLC, based on their expression in both tumor cells and tumor related stromal 
cells.  
More specifically we aimed to: 
• Investigate the immunohistochemical expression of MMP-2, -7 and -9  
• By in situ hybridization examine the expression of miR-21 and miR-182 
• Explore the prognostic impact of these molecular markers and their relation to 




3 MATERIALS AND METHODS 
3.1 Patients 
Between 1990 and 2004, 371 patients with pathological stage I to IIIA non-small cell 
lung cancer were diagnosed at the University Hospital of North Norway and Nordland Central 
Hospital. Out of 371 patients, 36 were excluded from the study due to radiotherapy or 
chemotherapy prior to surgery (n = 10), other malignancy within 5 years before NSCLC 
diagnosis (n = 13) or inadequate paraffin-embedded fixed tissue blocks (n = 13). Thus, 335 
patients with complete demographic and clinicopathological data were eligible. (Figure 4).  
 










Other malignancy within five 
years prior to NSCLC diagnosis.
N = 13
335 patients with complete  
medical records and adequate 
paraffin-embedded tissue blocks.  
Figure 4: Patient inclusion and exclusion 
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Demographic, clinical and histopathological variables are shown in Table 2. The most 
recent (third) disease-specific survival (DSS) update was done in January 2011. The median 
follow-up time of survivors was 105 months (range 73-204) and the median patient age was 
67 years. For the first paper, we used data from the update in November 2008. Based on the 




Table 2: Patient characteristics and their variables as predictors for disease-spesific survival  
in 335 NSCLC patients (univariate analyses; log-rank test). 
Characteristics Patients Median survival 5-year survival P 
 n (%) months %  
Age      
    ≤ 65 years 156 (47) 98 55 0.42 
    >65 years 179 (53) NR 60  
Sex      
    Female 82 (24) 190 64 0.22 
    Male 253 (76) 98 56  
Smoking      
    Never 15 (5) 19 43 0.26 
    Current 215 (64) NR 60  
    Former 105 (31) 84 55  
Performance status      
    PS 0 197 (59) NR 63 0.016 
    PS 1 120 (36) 64 52  
    PS 2 18 (5) 25 33  
Weight loss      
    < 10 % 303 (90) 190 58 0.76 
    > 10 % 32 (10) 98 57  
Histology      
    SCC 191 (57) NR 66 0.028 
    Adenocarcinoma 113 (34) 54 46  
    LCC 31 (9) 98 56  
Differentiation      
    Poor 138 (41) 47 47 < 0.001 
    Moderate 144 (43) 190 65  
    Well 53 (16) NR 68  
Surgical procedure      
    Lobectomy + Wedge* 243 (73) 190 62 0.007 
    Pneumonectomy 92 (27) 37 47  
Pathological stage      
    I 157 (47) NR 61 < 0.001 
    II 136 (40) 62 51  
    IIIa 42 (13) 17 23  
Tumor status      
    1 85 (25) 190 75 < 0.001 
    2 188 (56)  84 57  
    3 62 (19)  25 36  
Nodal status      
    0 232 (69) NR 67 < 0.001 
    1 76 (23) 35 43  
    2 27 (8) 18 18  
Surgical margins      
    Free 307 (92) 190 59 0.37 
    Not free 28 (8) 47 48  
Vascular infiltration      
    No 284 (85) 190 62 0.001 
    Yes 51 (15) 27 33  
*Wedge, n = 10 
Abbreviations: NR = not reached; PS = performance status; SCC = squamous cell carcinoma,  




3.2 Tissue Micro Array 
 Tissue micro arrays (TMAs) represent an efficient and cost effective way to 
investigate the molecular profile of a large tissue cohort. In 1986, Battifora introduced the 
multitumor block for immunohistochemical antibody testing of a large sample of tissue 
specimen (64). The method was refined, and in 1998 Kononen et al. published what is 
referred to as the first modern TMA study (65). The technique rapidly became a much used 
method in molecular profiling studies (66). 
On a single slide, cores from hundreds of specimen can be evaluated in one single 
operation. This method has revolutionized large scale investigations of molecular markers and 
their biological and prognostic features. Using methods as immunohistochemistry (IHC) or in 
situ hybridization (ISH), it is possible to perform high-throughput marker analyses on DNA, 
RNA or protein level.  
   
3.2.1 TMA construction  
Two pathologists reviewed all lung cancer cases histologically. The most 
representative paraffin donor blocks were chosen for each case, and then representative areas 
of tumor and stromal cells were selected and marked on the corresponding hematoxyline and 
eosine (H/E) slide and sampled for the recipient TMA blocks. With a tissue-arraying 
instrument (Beecher Instruments, Silver Springs, MD) TMAs were assembled using a 0.6mm 
thin walled stainless steel biopsy needle. The instrument was used to create holes in the 
recipient paraffin block to “home” tissue cores from the donor block. Two cores each of 
tumor cells and stromal cells were biopsied from the donor blocks and transferred to the 
recipient block. The recipient block was held in a X-Y position guide that was manually 
adjusted by micrometers. To include the entire 1340 cores of interest plus control cores, eight 
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tissue array blocks were constructed. Multiple 4-µm sections were cut with a Micron 
microtome (HM355S) and stained by specific antibodies for IHC or processed for in situ ISH 
analysis.   
 
Figure 5:  Construction of a microarray. Representative areas from each paraffin-
embedded, formalin-fixed donor tumor block are selected. 0.6-2.0 mm in diameter cores 
are punched and arrayed into a donor block. Sections of the resultant tissue microarray 
block are cut and transferred to a glass slide for processing of biomarker status by IHC 





3.2.2 TMA – advantages and disadvantages 
There are both advantages and disadvantages related to the use of the TMA 
technology. Table 3 summarizes some of these issues:  
 
Table 3: Advantages and disadvantages with TMA technology 
Advantages Disadvantages 
Time saving Can be technically challenging 
Cost saving Tempting to use otherwise not suited 
material 
Scoring by less trained personnel Lower accuracy when heterogenous 
expression 
Tissue saving Variation through the core 
Larger study cohorts Not suited for individual diagnosis 
Standardized staining conditions  
Sharing with other institutions  
 
 
Compared to using whole sections of tissues, with one slide for every patient, the benefits 
with the TMA technology are obvious. When the TMA blocks are made, it is time saving for 
the technician. With our material as an example, eight slides are cut instead of 335, and IHC 
or ISH can be done on these eight slides in one operation. Processing eight slides instead of 
335 will also save significant costs through reduced consumption of antibodies/probes and 
other reagents and material. It is time saving for the scorer(s), who immediately see the tumor 
areas or stromal areas in the microscope ready for scoring, and do not each time have to locate 
suitable areas on a whole section slide.  
Concerns have been raised about the representativity of 0.6 mm cores compared to 
whole section slides. The cores are biopsied from areas which are carefully selected and 
marked by pathologists, and comparisons have shown a correlation on 90-95% between 
scoring of TMA cores and whole sections when it comes to evaluation of larger cohorts (68-
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70). It is also possible to increase the representativity by increasing the number of cores from 
each patient (71). However, the TMAs are not well suited for diagnostic purposes, as the 
cores with diameters from 0.6 mm to 2 mm will not reflect variations in heterogeneous tissues 
(72).   
TMA slides are well suited for exchange between research institutions and laboratories. 
By exchanging stained slides, it is possible to compare scoring of slides and choice of cut-off 
values, while unstained slides make it possible to compare IHC or ISH procedures.  
Making good TMAs is dependent on dedicated and trained technicians. It is easier to 
embed and cut traditional blocks than to produce and cut TMAs. It is also important to 
remember that although it may be tempting to include as many patients as possible because of 
the features of the TMA technique, it is essential that the tissues have been processed in a 
similar way. By collecting tissues over a large time span, the chances for alteration in tissue 
processing techniques increase.     
  
3.3 Immunohistochemistry (IHC) 
IHC is a widely adopted method for detecting the expression of a given biological 
molecule, and it is considered the gold standard for in situ protein expression detection in 
tissue sections. In short, the method allows for the visualization of antigens by sequential 
application of a specific antibody to the antigen, a secondary antibody to the primary 
antibody, an enzyme complex and a chromogenic substrate. The enzymatic activation of the 
chromogen results in a visible reaction product (e.g. color) at the antigen site. The method has 
the advantage of being relatively inexpensive, it is established in most laboratories, it can be 
done on archival tissues and it is possible to evaluate expression in cells from different 
compartments of tissues. It is a multi-step process with potential pitfalls. To get a good result, 
an experienced technician is warranted. Often adaptations have to be made to find the best 
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set-up for antigen retrieval, incubation time of antibodies, dilutions, washing time and 
techniques. The TMA technique gives the advantage of standardization among all cores on 
the slide compared to staining of multiple whole tissue slides. 
3.3.1 Antibodies 
There are two principally different groups of antibodies used in IHC: Monoclonal and 
polyclonal antibodies. Polyclonal antibodies are a heterogeneous mixture of antibodies 
directed against various epitopes of the same antigen. Polyclonal antibodies are most 
frequently produced in rabbits, but also other animals are used. They are produced by 
immunizing the animal with an antigen. Three to eight months later blood is collected, and the 
antibody is purified. These antibodies can have slightly different affinities and specificities 
against the antigens.  
Monoclonal antibodies are a homogeneous population of immunoglobulin directed 
against a single epitope of the antigen. They are generated by a single B-cell clone and are 
therefore immunochemically similar. They are usually produced in rabbits and mice. After 
achieving a satisfying immune response, B-lymphocytes are isolated and fused with immortal 
myeloma cell lines. The new isolated cell line can produce antibodies either in a bioreactor 
system or cells can be injected into the peritoneal cavity of an animal.  
There are benefits to both groups of antibodies. The polyclonal antibodies are more 
robust, and there is a smaller chance for false negative results as the antibody recognizes 
various epitopes. But at the same time, recognizing more epitopes increases chances for cross-
reactivity. Monoclonal antibodies have the advantage of lot-to-lot consistency, since its 
production depends on an immortal monoclonal cell line and not on the life of the animal as 
with the polyclonal antibody production. Disadvantages may be weaker signal and a higher 
chance of false negative results.  
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3.3.2 IHC procedure  
 The 4 µm sections were deparaffinized with xylene and rehydrated with ethanol. 
Antigen retrieval was performed by placing the sections in 0.01 M citrate buffer at pH 6.0 and 
heating them in microwave oven for 20 min at 450W. The Vectastain elite ABC kit from 
Vector Laboratories was used for endogen peroxidase blocking. All primary antibodies were 
incubated overnight at 4˚C. The Vectastain kit was then used for detection with secondary 
antibodies, and the Vector NovaRed Substrate kit was used to visualize the target antigen with 
a brown color.  For each antibody, all the slides were handled in one single operation. As 
negative staining controls, the primary antibodies were replaced with the primary antibody 
diluent. Finally, all slides were counterstained with haematoxylin to visualize the nuclei.  
The antibodies used in this study were subjected to in-house validation by the 
manufacturer for IHC analysis on paraffin-embedded material.  
 
Table 4: Antibodies used in paper 1 
Antigen Type Manufacturer Catalog # Dilution 
MMP-2 Mouse monoclonal Abcam Ab7032 1:15 
MMP-7 Rabbit polyclonal Abcam Ab4044 1:15 
MMP-9 Mouse monoclonal Abcam Ab51203 1:100 
 
 
3.4 In situ hybridization (ISH) 
In situ hybridization is a technique that uses labelled complementary DNA or RNA 
strands to detect a specific DNA or RNA sequence in tissues. ISH is a method where 
background staining may be a problem. If so, it will be difficult to separate the nucleotide of 
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interest from the rest of the tissue. There are pitfalls with the ISH method which may cause 
background staining; a too high concentration of the labelled probe, too long hybridization 
time, or an inadequate post-hybridization wash may produce staining in areas where there are 
no nucleotides present. Besides, smaller probes (less than 25 nucleotides) traditionally have a 
much narrower window of signal to background, and are therefore more likely to produce 
background staining than longer probes (73). MicroRNAs are small in size, typically from 19-
22 nucleotides. For long, the small size made it hard to use ISH as a method for detecting 
miRs. The problem was solved when the locked nucleic acid (LNA) probe was developed, 
which fixes the small nucleotide in a three dimensional space and rises the melting 
temperature for the LNA probe and its complementary miR-sequence substantially.  
One of the main advantages using the ISH technique is that it allows us to study the 
molecular expression in cells in different compartments of tissues. Most previous studies have 
used polymerase chain reaction (PCR)-techniques to detect miRNAs. With PCR, the miRNAs 
you detect will originate from a mix of tumor cells and stromal cells. Our research group is 
among the first to use ISH technique with this purpose, and to our knowledge the very first on 
NSCLC.  
3.4.1 ISH procedure 
In situ hybridization was performed following the protocol developed by Exiqon, 
Vedbaek, Denmark (74). Digoxigenin (DIG) labelled locked nucleic acid (LNA) modified 
probes from Exiqon for miR-21 (has-miR-21), miR-182 (hsa-miR-182), positive control (U6, 
hsa/mmu/rno) and negative control (scramble-miR) were used in these papers. Some 
adjustments were done to get a specific and sensitive detection of miRNA in our sections 
from formalin-fixed paraffin-embedded (FFPE) TMA blocks.  
We placed 4 µm sections of the TMA blocks in a heater at 59˚C over night to attach 
cores to Super Frost Plus slides. Sections were deparaffinised with xylene (3 x 5 min) and 
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then rehydrated with ethanol solutions (99.9% - 96% - 70%) ending up in PBS, pH 7.4. 
Proteinase-K (20 µg/ml) (Exiqon, Vedbaek, Denmark) treatment was done in PK-buffer 
(5mM Tris-HCl, pH 7.5, 1mM EDTA, 1 mM NaCl, autoclaved) at 37˚C for 20 min in a  
HYBrite automated hybridizer (Abbot laboratories, IL, US). After a PBS wash the sections 
were dehydrated through increasing gradient of ethanol solutions and air-dried. The LNA-
probes were denatured by heating to 90˚C for 4 min. Hybridization of the LNA-probe miR-
182 (100nM) and scramble miR (50nM) control was carried out in the HYBrite automated 
hybridizer at 50˚C for 60 min. The positive control U6 (1nM) was hybridized at 55˚C for 60 
min. Stringent washes was performed in pre-heated SSC buffers, 1 x 5 min in 5x SSC, 2 x 5 
min in 1x SSC and 0,2x SSC. Sections were blocked against unspecific binding in blocking 
solution from DIG wash and Block Buffer set (Roche, Mannheim, Germany) for 15 min at 
room temperature (RT). Alkaline phosphatase (AP)-conjugated anti-DIG (Roche) 1:800 was 
incubated for 60 min at RT for immunologic detection. After PBS-T wash the substrate 
enzymatic reaction was carried out with NBT/BCIP (Roche) at 30˚C in the hybridizer for 120 
min. The reaction was stopped with a 2 x 5 min wash in KTBT buffer (50mM Tris-Hcl, 
150mM NaCl, 10mM KCl). Sections were counter stained with nuclear fast red (WALDECK, 
ZE-012-250) at RT for 1 min and then rinsed in tap water. Dehydration followed through 
increasing gradient of ethanol solutions and finally mounting with Histokitt mounting 
medium (Assistant-Histokitt, 1025/250). 
3.5 Scoring 
In paper 1 and 3, scoring was performed by light microscopy where representative and 
viable tissue sections were scored semiquantitatively for cytoplasmic staining. The dominant 
staining intensity in both tumor and stromal cells was scored as: 0 = negative; 1 = weak; 2 = 
intermediate; 3 = strong. The cell density of stroma was scored as: 1 = less than 25% positive 
cells; 2 = between 25% and 50% positive cells; 3 = more than 50% positive cells. In paper 2, 
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the ARIOL imaging system (Genetix, San Jose, CA) was used, and the cores were scored on a 
computer screen following loading and scanning of the slides. Tumor cells were scored as 
described for paper 1 and 3, while stromal cells were given a score from 0-3 based on both 
staining intensity and cell density.  
All samples were anonymized and independently scored by two pathologists in paper 
1 and 2, and one pathologist and one oncologist in paper 3. In a previous paper from our 
group, the interobserver scoring agreement in this material was calculated for two molecular 
markers (VEGF-C and VEGFR-3). The mean correlation coefficient (r) was 0.95 (range 0.93-
0.98) (75). 
Mean score for duplicate cores from each individual was calculated separately in 
tumor and stroma. Regarding paper 2, up to 4 cores was scored by each pathologist, because 
tumor cells if possible, were scored also in “stromal” cores and vice versa. High expression in 
tumor cells was defined as score >0 (miR-182), ≥0.5 (miR-21) and ≥2 (MMP-2, MMP-7, 
MMP-9). Stromal expression in MMP-2 and MMP-9 was calculated by summarizing intensity 
score (0-3) and density score (1-3). In miR-21, one score (0-3) was based on both intensity 
and density. High expression in stroma was defined as score >0 (mir-21), ≥3.5 (MMP-2) and 
≥ 4.5 (MMP-9).  
3.6 Cut-off values  
The expression of the biomarkers in our studies varies over a continuous scale, and is 
not a matter of negative or positive expression. The choice of a cut-off point is therefore an 
important issue. To standardize cut-off values is difficult, due to variations in methods 
including differences in tissue preparation, antigen retrieval, and assessment of positive 
staining. Using the mean value is an approach employed in many studies, but is not 
necessarily the best option. By using the mean value, there is a risk that biologically important 
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information is lost leading to false negative results (type 2 errors). On the other hand, the 
chance for false positive results decreases (type 1 errors), and the results may be easier to 
reproduce. In our studies, we have used cut-offs which gave the most difference in DSS 
between the subgroups while maintaining large enough subgroups. By this approach we 
expect to identify the biologically significant cut-offs. It would be of great value to get an 
independent validation of our results, and we now try to do this by expanding our own 
material (using specimen from one of the institutions as a validation set). We have also 
initiated collaboration with another lung cancer research group to establish a validation set. 
3.7 Controls and limitations 
Regarding the IHC-procedure, both reagent and tissue controls were used. Negative 
reagent control was preformed by replacing the primary antibody with a primary antibody 
diluent to rule out staining without the antibody. The positive control was done by staining 
tissues with a known expression pattern for the actual antibodies. This was done in lung 
cancer tissues, normal lung and in tissues from other organs. For the ISH procedure, negative 
control was done by using a miRNA-probe which is not complementary to any known human 
miRNA, a so called scramble-miR. For positive control, a U6 probe was used.  
To ensure that an antibody is specific, a western blot is done to confirm binding of a 
protein with the expected size. This procedure is normally done by the manufacturer of the 
antibody, and we have trusted their documentation. However, we have in our group lately 
performed some western blot procedures on selected antibodies to ensure that they are of 
proper quality.  
Another concern is that tissue storage over several years may affect the results. The 
oldest tissue blocks are dated back to 1990. Archival blocks dating back 20-40 years are 
considered adequate for evaluation provided initial fixation in 4% buffered formalin (70). We 
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did not experience any systematic variation between older and newer blocks when examining 
the slides 
3.8 Statistical analysis 
  Sample size was estimated with survival as the primary endpoint. At least a 50% 
increase in hazard ratio resulting from the presence of a specific marker was assumed to 
represent a clinically significant effect. The 5-year DSS for patients with resected NSCLC is 
about 60%, and the frequency of a given level of a specific marker is typically about 35%. 
Analyzing the primary endpoint in a proportional hazard regression with a specific marker at 
a specific level as a dichotomous independent variable, 300 subjects are necessary to achieve 
a power of 80% at an alpha of 5% (PASS 2002, Number Cruncher Statistical Systems, 
Kaysville, Utah, USA). This estimate does not take into account the testing of multiple 
markers in the actual analysis, and can only serve as a rough indication of the number of 
needed subjects.  
The statistical analyses were done using the package versions 17.0 and 19.0 from 
SPSS (Chicago, IL). In all three papers, the Chi-square test and Fishers Exact test were used 
to examine the association between molecular marker expression and various 
clinicopathological parameters. Univariate analyses were done using the Kaplan-Meier 
method, and the statistical significance between survival curves was assessed by the log-rank 
test. Disease-specific survival was determined from the date of surgery to the time of lung 
cancer specific death. The Cox proportional hazards model was used to assess the 
independent value of different pretreatment variables on survival, in the presence of other 
variables. Only variables of significant value from the univariate analysis were entered into 
the Cox regression analysis. Probability for stepwise entry and removal was set at .05 and .10, 




4 MAIN RESULTS 
4.1 Paper 1 (MMP-2, -7 and -9) 
This study aimed to explore the prognostic impact of MMP-2, -7 and -9 in tumor cells 
as well as in stromal cells of resected NSCLC tumors. MMP-2 and -9 were scored in both 
tumor and stromal cells, while MMP-7 was only possible to score in tumor cells.  
 
4.1.1 Correlations 
There was a strong correlation between high tumor cell MMP-2 expression and high 
stromal MMP-2 expression (r = 0.409, P < 0.001). Between molecular markers and 
clinicopathological variables, we found a moderate correlation between age > 65 years and 
both tumor cell and stromal cell expression of MMP-2 (r = 0.263, P < 0.001; r = 0.313, P < 
0.001, respectively).  
 
4.1.2 Univariate analyses 
MMP-2 expression was not significantly associated with DSS in tumor or stroma, but 
there was a tendency towards a better survival at high stromal MMP-2 expression (P = 0.053). 
High MMP-7 tumor cell expression was significantly associated with a favorable DSS (P = 
0.029). Also, patients with high stromal MMP-9 expression had a significantly better 
prognosis (P = 0.001). 
4.1.3 Multivariate analyses 
High tumor cell MMP-7 expression was an independent positive prognostic factor for 
DSS (HR 0.63, CI 95% 0.43 – 0.93). Also, high stromal MMP-9 expression was 
independently associated with a better prognosis (HR 0.52, CI 95% 0.34 – 0.80).
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4.2 Paper 2 (miR-21) 
In a pilot study, our group screened tumor tissues from 10 worst and 10 best prognosis 
NSCLC cases as well as 10 normal lungs for the expression of 281 miRNAs, among these 
several angiogenesis-related miRNAs (52). Quantified by microarray hybridization and 
validated by qRT-PCR, miR-21 had a four-fold change in tumor when compared to normal 
NSCLC tissues. Previous results on miR-21 had been conflicting, and we wanted to explore 
the impact of miR-21 on DSS in our large NSCLC cohort. miR-21 was assessed in tumor and 
stromal cells. 
4.2.1 Correlations 
We did not observe any significant correlation between miR-21 and the angiogenesis-
related protein markers protein kinase B (Akt), phosphatidylinositol-3-kinase (PI3K), hypoxia 
induced factor 1 (HIF1α) or VEGF-A.  
4.2.2 Univariate analyses 
Tumor cell expression of miR-21 had no significant impact on DSS when assessed in 
the overall NSCLC cohort. In subgroup analyses of node positive patients, high tumor cell 
expression of miR-21 was associated with a better prognosis compared to low expression (P = 
0.024).  In stroma of all patients, high miR-21 expression was a negative prognostic indicator 
(P = 0.022). This was also the case in the node-negative patients (P = 0.044). 
4.2.3 Multivariate analyses 
 miR-21 expression had no independent impact on survival in the whole cohort. In 
node positive patients, however, low tumor cell expression was independently associated with 
a worse prognosis (HR 2.03, CI 95% 1.09 – 3.78).  
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4.3 Paper 3 (miR-182) 
In the same pilot study as referred to for paper 2, miR-182 was the only miRNA to be 
up-regulated in all three comparisons: worst prognosis versus normal lung, best prognosis 
versus normal lung and worst prognosis versus best prognosis (52). From previously 
published studies, miR-182 was often reported up-regulated in cancers. But the results were 
highly conflicting regarding the impact of miR-182 as an oncogene or as a tumor suppressor. 
This made it interesting for us to explore this miRNA in a large NSCLC cohort. miR-182 was 
expressed only in tumor cells. 
4.3.1 Correlations 
We found significant, although weak, correlations between miR-182 and fibroblast 
growth factor 2 (FGF2) (r = -0.147; P = 0.010), HIF2α (r = 0.115; P = 0.047) and MMP-7 (r = 
0.172; P = 0.003). 
4.3.2 Univariate analyses 
In the whole cohort there was a tendency towards a better prognosis for patients 
expressing high tumor cell miR-182 (P = 0.062). In subgroup analyses, we found a 
significantly improved survival for those expressing high miR-182 in stage II patients (P = 
0.003) and in patients with SCC (P = 0.042). 
4.3.3 Multivariate analyses 
High tumor cell miR-182 tended to a positive prognostic impact for the whole cohort, 
but the multivariate analysis did not reach statistical significance (HR = 0.73, CI 95% 0.50 – 
1.06). In subgroup analyses, however, we found high miR-182 expression in tumor cells to be 
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an independent positive prognostic factor in stage II patients (HR 0.50, CI 95 % 0.28 – 0.90) 
and in the histopathological SCC subgroup (HR 0.57, CI 95% 0.33 – 0.99). 
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5 DISCUSSION 
5.1 A summary of strengths and weaknesses 
We have a relatively large sample size with hardly any selection bias, as the cohort 
includes 90% of all operated stage I-IIIA NSCLC patients in our region during the specified 
period. The follow up time is significant, and we have performed a comprehensive collection 
of clinical data. We have also validated the data by contacting the local hospital or the 
patients’ physician in cases of inadequate or missing data in the hospital journals. Staging and 
pathological diagnosis was revised by two experienced pathologists. For the TMAs, duplicate 
cores were taken from both tumor cell areas and stromal cell areas of the tissue blocks. The 
TMA production and the IHC and ISH procedures were performed by dedicated and 
experienced technicians. We assessed protein expression and microRNA expression both in 
stromal cells and neoplastic cells. The optimal cut-offs reduced chances of false negative 
results (type 2 errors).  
A weakness may be that we did not perform any validation of the antibodies used in 
paper 1. However, in-house validation had been done by the manufacturer. Furthermore, 
using optimal cut-offs and not predefined or mean value cut-offs, the chance of false positive 
results (type 1 errors) increase. Another weakness is the unavailability of an external 
validation set.   
5.2 Paper 1 
In the first paper we explored the three matrix metalloproteinases MMP-2, MMP-7 
and MMP-9. Our main conclusion was that high tumor cell MMP-7 and stromal MMP-9 
expressions were independent positive prognostic factors in NSCLC. MMP-2 expression did 
not have any prognostic implications in our cohort. 
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We are the first researchers to find a positive prognostic impact of MMP-7 expression 
in NSCLC. From four small-sized previous studies on NSCLC and MMP-7 expression, two 
reported no impact on survival (76;77), while the other two found an independently worsened 
survival connected to high MMP-7 expression (78;79). A recently published paper failed to 
show any MMP-7-dependent impact on survival (80). However, consistent with our NSCLC 
data, high MMP-7 expression has been associated with a better survival in other tumor types. 
In salivary gland carcinoma and in papillary thyroid carcinoma, MMP-7 was related to an 
improved outcome (81;82) 
We found no impact on DSS connected to MMP-9 expression in the tumor cells. High 
stromal expression of MMP-9, however, was independently associated with a good prognosis. 
Two papers reporting on stromal MMP-9 expression in NSCLC failed to show any impact on 
survival (76;83). In these studies, both patient cohorts were smaller than ours.  
Since MMPs traditionally have been viewed as oncogenes, MMP inhibitors were 
invented as drugs in cancer treatment (37;84;85). Randomized trials with these MMP 
inhibitors failed, however, to show positive survival results. It is speculated whether the lack 
of effect is related to the complex pro- and antitumorigenic properties of MMPs. 
The MMPs have complex functions. The MMPs of this paper have traditionally been 
connected to degradation of the extracellular matrix, but it is also well known that they 
contribute to signalling for cell growth, inflammation and angiogenesis (36;37) Functional 
studies have demonstrated that they can contribute to both tumor progression and tumor 
suppression (86-88). Among studies supporting the notion that MMP-7 may serve a protective 
role in lung cancer and thereby corroborating our results, is the one by Abdel-Ghany et al., 
which showed that MMP-7 inhibited lung cancer cell adhesion to lung endothelium (86). 
Besides, Acuff et al. found MMP-7 positive mice to form fewer lung tumors than MMP-7 null 
mice (87). Studies on MMP-9 have shown divergent impacts on tumor development. Skin 
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carcinomas in MMP-9-null mice were found to increase in number, but acted less aggressive 
than in mice with normal MMP-9 levels (89). In another study, higher MMP-9 levels were 
associated with more lung metastasis, but the subsequent growth of metastases was not 
affected by MMP-9 levels (87). 
 MMPs are associated with angiogenesis, and in a stimulatory fashion through their 
role in the angiogenic switch (38). But also here, their dual roles are evident, as they 
contribute to the release of several antiangiogenic factors. Both MMP-7 and -9 are known 
generators of angiostatin, a cleavage product of plasminogen. In mice, Pozzi et al. found a 
link between lower levels of MMP-9 and angiostatin, and a subsequent increase in tumor 
growth (90). The same MMPs produce endostatin, another angiogenesis inhibitor, from the 
basement membrane type XVIII collagen. Endostatin is associated with angiogenesis 
inhibition and reduced tumor growth in animal models (91;92). Finally, MMP-9 cleavage of 
basement membrane collagen IVα3 generates tumstatin. Lower levels of this angiogenesis 
inhibitor are found to increase pathological angiogenesis and tumor growth (93).  
We found a protective impact of MMP-7 and MMP-9, a result somewhat conflicting 
earlier studies and the established understanding of how these MMPs work. However, we 
have pointed out some possible explanations for our results. Our cohort is large, which makes 
our numbers more reliable. Further, studies on other tumor types are consistent with our 
results. We also discuss several studies which can explain why these MMPs may have tumor 
protecting features, and our results contribute to the understanding why the MMP inhibitors 
failed in clinical studies. Anyway, it is necessary to explore this field further. Validation in 
other cohorts would be warranted. It will also be of interest to see further functional studies.  
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5.3 Paper 2 
In this paper, we investigated the impact of miR-21 in NSCLC. We found high tumor 
cell miR-21 expression in patients with lymph node metastasis to be an independent positive 
prognostic factor. For stromal cell expression of miR-21, we observed an opposite trend with 
high expression associated with a negative prognosis in the univariate analysis.    
Our study is the first using ISH-technique for high throughput exploration of miR-21 
expression, assessing its prognostic impact in NSCLC. There are a few previous publications 
in this field, most using qRT-PCR to assess the prognostic impact of miR-21 in NSCLC. 
Some of these publications find, inconsistent with our results, miR-21 to be a negative 
prognostic factor (94-96), while others find no prognostic impact of miR-21 (97;98).  
One plausible reason for our divergent results when compared to some of the other 
studies, may be the fact that we used ISH, enabling us to assess tumor cells and stromal cells 
individually. In contrast, PCR can only give one overall assessment for the tissue investigated. 
So, in the previous studies it could not be discriminated between tumor and stromal cells, as 
the authors did not microdissect tumor cells versus stromal cells. With respect to our data, the 
positive contribution from miR-21 in tumor cells may have overridden possible negative 
contribution from the stroma. In line with this, Gregg and colleagues observed in prostate 
cancer a large difference regarding gene expression between cells of the tumor respective 
stromal compartment (99).  
As miR-21 regulates a number of various genes, it may contribute to both tumor 
progression and suppression. Consistently, functional studies have revealed that miR-21 can 
act both pro- and anti-angiogenic. The proangiogenic features were shown in human prostate 
cancer cells, where miR-21 through up-regulation of HIF-1α and VEGF and activation of the 
Akt and extracellular regulated kinases (ERK) pathways induced angiogenesis (100). Sabatel 
and colleagues used human umbilical vein endothelial cells (HUVECs) to demonstrate 
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possible angiogenesis inhibiting properties from miR-21 (101). Via inhibition of RhoB (ras 
homolog gene family, member B), endothelial proliferation and migration was reduced, 
leading to reduced vessel formation. It is possible that these pro- and anti-angiogenic 
properties dominate in different stages of the disease, and this may explain the difference we 
find for miR-21 impact between node negative and node positive patients.  
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5.4 Paper 3  
In the last paper, we investigated the possible impact of miR-182 on the NSCLC 
prognosis. We found high tumor cell miR-182 expression in stage II patients and in SCC to be 
an independent favorable prognostic factor. In the whole cohort, high miR-182 expression 
tended to a favorable outcome without reaching statistical significance. miR-182 was not 
detected in stromal cells. 
We have identified one smaller NSCLC study with 70 cases, in which the prognostic 
impact of miR-182 was explored (102). The authors found miR-182 to be a negative 
prognostic factor. They used PCR, not ISH, to detect miR-182 expression. In one study of 253 
glioma patients using ISH, high miR-182 expression was a negative prognosticator (103). In 
another study on 148 colorectal patients, a similar conclusion was reached (104). Thus, these 
studies conclude opposite from our study.   
In the literature, miR-182 has mainly been regarded as an oncogene. It is interesting to 
see, though, that many functional studies and studies on cell cultures find tumor suppressing 
properties connected to miR-182, supporting the conclusion in our study. In one study by 
Poell and coworkers, miR-182 was found to be a strong inhibitor of melanoma cell line 
proliferation  (105). Supporting these findings, Yan et al. following transfection of miR-182 
into cultured uveal melanoma cells, found a significant decrease in cell growth, migration and 
invasiveness (106). Microphthalmia-associated transcription factor (MITF), B-cell lymphoma 
2 (BCL2) and cyclin D2 are believed to be targets of miR-182 leading to these tumor 
suppressing properties. There are also two studies on lung tumors corroborating our 
conclusion on miR-182 as a possible tumor suppressor. miR-182 was found to suppress lung 
tumorigenesis through regulation of Regulator of G-protein signaling 17 (RGS17) (107). 
Also, Zhang and coworkers found that invasion and proliferation of human lung 
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adenocarcinoma cells were inhibited via miR-182’s effect on human cortical actin-associated 
protein (CTTN) (108).  
miR-182 is also found to be differently expressed between primary tumors and 
metastases in the same organ (109;110). Other studies have revealed different expression 
profiles of miRNAs in AC and SCC of the lung (111). These findings indicate that miRNAs, 
and also miR-182 in particular, can be stage- and tissue specific. It may explain why miR-182 
can have a prognostic impact in subgroups, even when a significant impact can not be seen 
for the whole cohort.  
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6 CONCLUSIONS AND IMPLICATIONS FOR FURTHER 
RESEARCH 
  
We have been studying two different classes of markers, which are angiogenesis-
related. We started with the MMPs, which are known to be important players in tumor 
angiogenesis, although they also have many other important functions. We found high 
expression of two of the MMPs to be significantly associated with an improved survival. We 
believe that the conflicting results from studies on MMP’s prognostic impact in NSCLC and 
other cancers may explain the lack of positive results from large clinical phase III studies with 
MMP inhibitors. MMPs have angiogenesis stimulating features, but they also contribute to 
angiogenesis inhibition through release of natural angiogenesis inhibitors.  
Research on MicroRNAs is a fast growing field, but there still is a long way before we 
can begin to get a functional overview of the vast number of different miRNAs. Our group is 
among the first to use ISH to perform large scale expression studies on miRNAs, at least in 
NSCLC. We believe that the distinction between tumor cells and stromal cells which the ISH 
methodology allows us to make, can contribute to new knowledge from more precise 
expression patterns and functions of miRNAs. We believe that the dissimilar prognostic 
impact of miR-21 depend on whether the methods used were cell specific or based on RT-
qPCR. Our main results are from subgroups, and may underscore the complex functions of 
miRNAs with discrepant impacts in different compartments. There are functional studies 
showing miR-21 and miR-182 to act both pro- and antiangiogenic, hence acting as oncogenes 
as well as tumor suppressors. These findings may predict that it might be challenging to 
develop drugs targeting miRNA, either in the form of inhibitors or stimulators. 
Although we have a large NSCLC material, a weakness of our work is the lack of 
validation cohorts. A solution is to establish a validation cohort through the collaboration with 
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another research group. This development is in progress. We are also expanding our own 
cohort by collecting tissue and data on patients operated in “our” hospitals between 2005 and 
2010. We will then have the possibility to split our cohort between patients operated in our 
two hospitals (Tromsø and Bodø), using one of the groups as a validation set.  
A major strength of our lung cancer research is the establishment of a large data set 
over time, with far beyond 100 molecular markers examined, and the number still rising. This 
facilitates exploration on relations between markers with potentially biological interactions. 
Our research team will continue to explore new groups of molecular markers. In the near 
future, we will investigate the potential impacts by immune cells and chemocines and 
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